← Back to Search

Treatment for Multiple Myeloma

N/A
Recruiting
Led By Irene Ghobrial, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered. Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study. This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA

Eligible Conditions
  • Multiple Myeloma
  • Blood Cancers
  • B-Cell Lymphoma
  • Myelodysplastic Syndrome
  • Monoclonal Gammopathy of Uncertain Significance
  • Waldenstrom Macroglobulinemia
  • Monoclonal Gammopathy
  • Chronic Lymphocytic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,100 Previous Clinical Trials
343,097 Total Patients Enrolled
52 Trials studying Multiple Myeloma
33,625 Patients Enrolled for Multiple Myeloma
The Leukemia and Lymphoma SocietyOTHER
85 Previous Clinical Trials
16,294 Total Patients Enrolled
12 Trials studying Multiple Myeloma
1,225 Patients Enrolled for Multiple Myeloma
Irene Ghobrial, MD4.25 ReviewsPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
11 Previous Clinical Trials
31,075 Total Patients Enrolled
7 Trials studying Multiple Myeloma
30,890 Patients Enrolled for Multiple Myeloma
~1029 spots leftby Dec 2025